Linked Life Data

2898321

Source:http://linkedlifedata.com/resource/pubmed/id/2898321

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1988-8-4
pubmed:abstractText
A double-blind controlled trial was carried out in 50 patients with anxiety neuroses to compare the effectiveness of metaclazepam, a recently developed benzodiazepine with anxiolytic activity, and bromazepam. Patients were allocated at random to receive treatment for 13 days with either 15 mg metaclazepam or 4 mg bromazepam per day, in 2 divided doses. The patients' anxiety status was assessed on entry and after 7 and 13 days of treatment by the physician, using the Hamilton multi-factorial rating scale, and by the patients, using a self-assessment rating scale. Both drugs produced a highly significant reduction in mean total scores, improvement being evident by the Day 7 assessment. Correlation between scores on the two scales was significant at all time points. Metaclazepam, however, was rated as producing a significantly greater improvement from baseline than with bromazepam on the self-rating scale.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-7995
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
45-7
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
A double-blind comparison of the anxiolytic activity of two benzodiazepines, metaclazepam and bromazepam, in anxiety neurosis.
pubmed:affiliation
Psychiatric Service USL, Legnano-Nogara, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial